

899 NORTH CAPITOL ST. NE – 2<sup>ND</sup> FLR.  
WASHINGTON, DC 20002

October 3, 2019

9:30am-11:30 am

## OPEN SESSION AGENDA

**Board of Pharmacy Mission Statement:**

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

**CALL TO ORDER:**

**PRESIDING:**

**BOARD MEMBERSHIP/ATTENDANCE:**

<b>BOARD MEMBERS:</b>		
	DR . TAMARA McCANTS, PHARM.D. R.PH CHAIRPERSON	
	MR. JAMES APPLEBY, R.PH VICE CHAIR	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	MR. ALAN FRIEDMAN, R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	CHIKITA SANDERS, CONSUMER BOARD MEMBER	
<b>STAFF:</b>	SHAUNA WHITE, EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, HEALTH LICENSING SPECIALIST	
<b>LEGAL STAFF:</b>	CARLA WILLIAMS, ASSISTANT GENERAL COUNSEL	
<b>VISITORS:</b>		

## Open Session Agenda

### Quorum:

<b>Introduction:</b>	None	
<b>1003-O-01</b>	<b><u>Approval of the Open Session Meeting Minutes</u></b>  (a) September 5, 2019 (b) August 1, 2019	
<b><u>Consent Agenda</u></b>	<b>None</b>	
<b><u>Executive Director Report</u></b>	<b><u>Licensing Report</u></b>  Statistics Prescription Monitoring Program Update Opioid Strategic Plan NABP Updates DC Board of Pharmacy CE Audit Update DEA Take Back Day: October 26, 2019	
<b><u>Assistant General Counsel Report</u></b>		Carla Williams
<b>1003-O-02</b>	Clinical Lab Practitioner Advisory Committee Updates  (a) Clinical Laboratory Practitioners Amendment Act of 2014 B20-0289	
<b><u>Subcommittee Report</u></b>		
	<b><u>Legislative and Regulatory</u></b>	
<b>1003-O-03</b>	Defending Access to Women’s Health Care Services Amendment Act of 2017	Mr. Alan Friedman
<b>1003-O-04</b>	<b><u>Communications Subcommittee Report</u></b>	
<b>NABP E-Newsletter</b>	<b><u>September 11, 2019</u></b>  NABP Launches New Consumer Website  Missouri Board of Pharmacy Accepting Applications for CS Drug Take Back Program  CDC Awards New Funds to Reduce Opioid Overdose Deaths	Dr. Shauna White

	<p>Plastikon Healthcare Recalls Milk of Magnesia Oral Suspension Due to Microbial Contamination</p> <p><b><u>June 19, 2019</u></b></p> <p>Hurricane Dorian Prompts State of Emergency in Five States (Florida, Georgia , North Carolina, South Carolina, and Virginia)</p> <p>NABP Model Act Updated to Address Suspicious Orders, PMP Reporting for Veterinarians, and More</p> <p>DEA Announces Steps to Improve Access to Marijuana Research</p> <p>Forty-One People Face Charges for Diversion of Prescription Medication Press Release: <a href="https://www.justice.gov">https://www.justice.gov</a></p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: <a href="https://nabp.pharmacy/newsroom/news/">https://nabp.pharmacy/newsroom/news/</a></p>	
<p><b><u>Matters for Board Consideration</u></b></p>		
<p><b>1003-0-05</b></p>	<p><b>Access to Biosimilars Amendment Act of 2019</b></p> <p>This legislation was developed by the Medical Society of the District of Columbia. The bill will amend the District of Columbia Prescription Drug Price Information Act to authorize licensed pharmacists to dispense interchangeable biological products, and to require notifications to physicians when such interchangeable biological products are dispensed.</p> <p>This information is brought before The Board for review and feedback.</p>	
<p><b>1003-O-06</b></p>	<p><b>License Examination Testing Accommodation Policy</b></p> <p>The DC Board of Pharmacy is interested in establishing guidelines for candidates that are requesting for exam testing accommodations.</p> <p>The Board thought it would be beneficial to contact the Virginia Board of Pharmacy for guidelines in establishing a policy regarding this matter.</p> <p><b>Virginia’s Regulation regarding testing accommodations:</b></p> <p><b>18VAC110-20-60</b></p> <p>F. If an applicant requests a testing accommodation for either examination based on a physical or mental impairment that substantially limits one or more major life activities, subject to the Americans with Disabilities Act, the board may approve a reasonable accommodation that does not compromise the security or integrity of the examination.</p>	

	<p>1. Supporting documentation shall be provided by the applicant to include the following to be considered for review: a. A letter of request from the candidate that specifies the testing accommodation requested;</p> <p>b. A written report of an evaluation (educational, psychological, or physical) within the preceding two years from a qualified professional that states a diagnosis of the disability, describes the disability, recommends specific accommodations, and provides justification that the accommodation is appropriate and necessary for the diagnosed disability. If the comprehensive evaluation was done more than two years ago and the condition is one that is not subject to change, the original evaluation report may be submitted along with a current letter from the qualified professional stating that there has been no change in the condition since the time of the evaluation; and</p> <p>c. A written statement from the appropriate person at the applicant's school of pharmacy that describes any testing accommodations made while the student was enrolled, if applicable.</p> <p>2. The applicant will be notified in writing of the decision. If the request for accommodation is granted, the approval information will be forwarded to the examination contractor and the form of the accommodation will be coordinated with the contractor.</p>	
<p><b><u>Public Comments</u></b></p>		
<p><b>Motion to Adjourn the Open Session</b></p>	<p>"Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." (Roll Call Vote)</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

**Open Session Meeting Adjourned at \_\_: \_\_**

**This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at [opengovoffice@dc.gov](mailto:opengovoffice@dc.gov).**